Artur Schmidtchen
Corporate Officer/Principal at University of Lund
Artur Schmidtchen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| University of Lund | Corporate Officer/Principal | - | - |
Career history of Artur Schmidtchen
Former positions of Artur Schmidtchen
| Companies | Position | Start | End |
|---|---|---|---|
Sista versen 26366 AB
 Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Founder | 25/10/2009 | - |
DermaGen AB
 DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Director/Board Member | 30/04/2004 | - |
| Founder | 19/07/2011 | - |
Statistics
International
| Sweden | 4 |
Operational
| Founder | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
DermaGen AB
DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Health Technology |
Sista versen 26366 AB
Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Health Technology |
- Stock Market
- Insiders
- Artur Schmidtchen
- Experience